Navigation Links
BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
Date:8/16/2013

BOSTON A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication. The five-year grant will focus on identifying microRNA biomarkers in heart disease.

Each year, complications from heart attacks (myocardial infarctions) contribute to more than half a million cases of heart failure and 300,000 cases of sudden cardiac arrest, when the heart suddenly stops. Both of these conditions are closely related to a process known as remodeling, in which the structure and function of the heart changes or remodels -- following a heart attack.

"Our goal is to explore the role that microRNAs play in predicting which heart-attack patients will go on to experience complications," explains Das, an electrophysiologist in BIDMC's Cardiovascular Institute and co-director of the cardiovascular genetics program within the Outpatient Cardiovascular Clinic.

"Current strategies used to identify the highest risk patients have often been inaccurate," he adds. "We think that a blood test that makes use of microRNA biomarkers could replace existing strategies and more accurately predict which patients might experience poor outcomes and thereby identify who would most benefit from frequent monitoring and medical care." Other investigators who are part of the NIH grant, "Plasma miRNA Predictors of Adverse Mechanical and Electrical Remodeling After Myocardial Infarction," include BIDMC Director of Cardiovascular Research Anthony Rosenzweig, MD, and BWH investigators Raymond Y. Kwong, MD, MPH, and Mark Sabatine, MD, MPH.

microRNAs are one type of extracellular RNA. Once considered nothing more than genomic "junk," microRNAs have more recently been recognized as playing a key role in cellular functions. Several years ago, scientists began to recognize that these small, noncoding RNAs were not only found inside cells, but could also be found in blood and other tissue fluids.

Using patient plasma samples from extensively characterized patients who have suffered heart attacks, the scientific team will first identify which specific microRNAs are related to poor heart remodeling. They will then use cell culture and animal models of heart disease to further prioritize which microRNAs play a functional role in disease progression. Finally, the investigators will validate these prioritized microRNAs as prognostic markers for poor health outcomes after heart attacks in a large prospective clinical trial.

"Ultimately, we think that miRNA-based tests could replace current tests to predict which patients might be at risk of complications and, therefore, be good candidates to receive an implanted defibrillator," says Das. "At the same time, we hope to be able to better predict which individuals are at less risk of complications and thereby spare them unnecessary and costly procedures."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related biology news :

1. New research points to benefits of eggs, even for those at cardiovascular risk
2. Cell-permeable peptide shows promise for controlling cardiovascular disease
3. New therapy for heart failure may enhance bodys stem cell response at cardiovascular injury site
4. FASEB SRC announces conference registration open for: Neural Mechanisms in Cardiovascular Regulation
5. Bilirubin can prevent damage from cardiovascular disease
6. Daily multivitamin use does not reduce cardiovascular disease risk in men
7. Strawberries activate protection protein to prevent cardiovascular disease
8. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
9. Tax on salt could reduce cardiovascular disease deaths by 3 percent
10. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
11. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical ... Physik Instrumente USA, have been selected as this year’s recipients of two top awards ... have been invited along with other honorees to accept their awards at a banquet ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model Aeronautics ... Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching a ... competition, and success through a STEM-based education platform. , Much like the program ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, ... engages Timothy Reinhardt to manage the new site. , Tim has 25 years ... his most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an innovation leader ... & Technologien GmbH, thereby expanding its product portfolio to include allergy and food ... asthma, atopic eczema or a food allergy. Allergies are escalating to epidemic proportions ...
Breaking Biology Technology: